Image: Bardy Diagnostics CAM patch (Photo courtesy of Bardy Diagnostics, Inc.)
The Carnation Ambulatory Monitor (CAM) patch from Bardy Diagnostics, Inc. (Seattle, WA, USA) was selected for use in protocols for measuring QT segments in COVID-19 patients prescribed hydroxychloroquine (HCQ). The CAM patch will be used in newly established protocols at hospitals in the Seattle, Washington area to monitor the heart rhythms of COVID-19 patients on HCQ after hospital discharge, as well as for outpatients. HCQ in some populations has been shown to prolong the QT interval, resulting in a life-threatening arrhythmia called Torsades de Pointes. The unique ability of the Bardy Diagnostics CAM patch to detect and record low frequency, low amplitude heart rhythms is particularly useful for measuring QT intervals and diagnosing torsades de pointes.
Bardy Diagnostics is an innovator in digital health and remote patient monitoring, with a focus on providing the industry’s most accurate and diagnostic-friendly cardiac monitors. The company’s CAM Patch is a non-invasive, P-wave centric ambulatory heart monitor and arrhythmia detection device designed to improve patient compliance in adults and children with its form factor tailored to the mode of life. Designed to be worn comfortably and discreetly for up to 14 days, the female-friendly hourglass-shaped CAM patch is placed in the center of the chest, directly over the heart for optimal ECG signal collection. Proprietary CAM patch technology provides optimal detection and clear recording of the often difficult to detect P wave, the ECG waveform signal that is essential for accurate arrhythmia diagnosis.
A peer-reviewed clinical study comparing the company’s CAM patch and a traditional Holter monitor demonstrated that the QT, PR, and QRS intervals measured by the CAM patch correlated with measurements taken by a traditional 3-channel device (6 leads) Holter monitor, resulting in correlation coefficients of 0.94, 0.93 and 0.86, respectively. In addition, the study showed a fourfold increase in the detection of arrhythmias using the CAM patch, including missed or misidentified arrhythmias using the Holter monitor. The study concluded that the CAM patch offered significantly improved rhythm diagnostics compared to a traditional Holter. The clinical value of the P-wave centric engineering of the CAM patch has also been demonstrated in a comparative clinical study between the CAM patch and the Zio® XT patch from iRhythm. This study, also published in the American Heart Journal, concluded that the BardyDx CAM patch identified 40% more arrhythmias and resulted in better and more informed clinical decision making in 41% of patients compared to the iRhythm Zio XT patch.
“The world is currently at war with the COVID-19 virus and we are proud that the CAM patch is being used in this fight to help physicians better identify and understand arrhythmias or other heart irregularities that may be related to the use of HCQ. . in COVID-19 patients, as well as the impact of any potential COVID-19 vaccine on heart function, ”said electrophysiologist Gust Bardy, MD, founder, CEO and medical director of Bardy Diagnostics.
“The CAM patch is quickly becoming the new standard of care in cardiac monitoring and the trusted cardiac monitor of choice for electrophysiologists, cardiologists and other physicians in the United States, United Kingdom and Canada,” said Ken Nelson, Chief Commercial Officer . “It’s increasingly clear that physicians and patients are realizing the true clinical and business differentiation value of our P-wave-driven sensing technology to optimize patient care and clinical workflow. “
Bardy Diagnostics, Inc.